LIB Therapeutics Preparing To Launch New PCSK9 Inhibitor Option Lerochol

Solo US Launch, Ex-US Partners

Lerochol is approved for hypercholesterolemia and HeFH, with a filing planned in HoFH (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business